Costanza Paoletti

Costanza Paoletti

Auto-generated profile, based on publicly available information

Costanza Paoletti

University of Florence

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 September 2013 in Nature Nanotechnology
Verified
Journal Article
Open access
PDF file
HYHyeun Joong Yoon
Hyeun Joong Yoon
TKTae Hyun Kim
Tae Hyun Kim
ZZZhuo Zhang
Zhuo Zhang
EAEbrahim Azizi
Ebrahim Azizi
TPTrinh M. Pham
Trinh M. Pham
SNSunitha Nagrath
Sunitha Nagrath
The spread of cancer throughout the body is driven by circulating tumour cells (CTCs)1. These cells detach from the primary tumour and move from the bloodstream to a new site of subsequent tumour growth. They also carry information about the primary tumour and have the potential to be valuable biomarkers for disease diagnosis and progression, and for the molecular characterization of certain biological properties of the tumour. However, the limited sensitivity and specificity of current methods for measuring and studying these cells in patient blood samples prevents the realization of their full clinical potential. The use of microfluidic devices is a promising method for isolating CTCs2,3. However, the devices are reliant on three-dimensional structures, which limits further characterization and expansion of cells on the chip. Here we demonstrate an effective approach to isolating CTCs from blood samples of pancreatic, breast and lung cancer patients, by using functionalized graphene oxide nanosheets on a patterned gold surface. CTCs were captured with high sensitivity at a low concentration of target cells (73 ± 32.4% at 3–5 cells per ml blood).

1 December 2016 in Clinical Biochemistry
Verified
Journal Article
Closed access
QKQing Kang
Qing Kang
NHN. Lynn Henry
N. Lynn Henry
CPCostanza Paoletti
Costanza Paoletti
Hui JiangHui Jiang
Hui Jiang
PVPankaj Vats
Pankaj Vats
MTMuneesh Tewari
Muneesh Tewari

6 November 2012 in Cancer and Metastasis Reviews
Verified
Journal Article
Open access
PDF file
FBFrancois-Clement Bidard
Francois-Clement Bidard
TFTanja Fehm
Tanja Fehm
MIMichail Ignatiadis
Michail Ignatiadis
JSJeffrey B. Smerage
Jeffrey B. Smerage
Catherine Alix-PanabieresCatherine Alix-Panabieres
Catherine Alix-Panabieres
JPJean-Yves Pierga
Jean-Yves Pierga
In 2004, circulating tumor cells (CTC) enumeration by the CellSearch® technique at baseline and during treatment was reported to be associated with prognosis in metastatic breast cancer patients. In 2008, the first evidence of the impact of CTC detection by this technique on survival of cM0(i+) patients were reported. These findings were confirmed by other non-interventional studies, whereas CTC were also investigated as a surrogate for tumor biology, mainly for HER2 expression/amplification. The aim of this report is to present the current prospective large interventional studies that have been specifically designed to demonstrate that CTC enumeration/characterization may improve the management of breast cancer patients: STIC CTC METABREAST (France) and Endocrine Therapy Index (USA) assess the CTC-guided hormone therapy vs chemotherapy decision in M1 patients; SWOG0500 (USA) and CirCe01 (France) assess the CTC count changes during treatment in metastatic patients; DETECT III (M1 patients, Germany) and Treat CTC (cM0(i+) patients, European Organization for Research and Treatment of Cancer/Breast International Group) assess the use of anti-HER2 treatments in HER2-negative breast cancer patients selected on the basis of CTC detection/characterization. These trials have different designs in various patient populations but are expected to be the pivotal trials for CTC implementation in the routine management of breast cancer patients.

14 February 2016 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
DCDavid Chu
David Chu
CPCostanza Paoletti
Costanza Paoletti
CGChristina Gersch
Christina Gersch
DVDustin A. VanDenBerg
Dustin A. VanDenBerg
DZDaniel J. Zabransky
Daniel J. Zabransky
BPBen Ho Park
Ben Ho Park
Purpose: Mutations in the estrogen receptor (ER)α gene, ESR1, have been identified in breast cancer metastases after progression on endocrine therapies. Because of limitations of metastatic biopsies, the reported frequency of ESR1 mutations may be underestimated. Here, we show a high frequency of ESR1 mutations using circulating plasma tumor DNA (ptDNA) from patients with metastatic breast cancer. Experimental Design: We retrospectively obtained plasma samples from eight patients with known ESR1 mutations and three patients with wild-type ESR1 identified by next-generation sequencing (NGS) of biopsied metastatic tissues. Three common ESR1 mutations were queried for using droplet digital PCR (ddPCR). In a prospective cohort, metastatic tissue and plasma were collected contemporaneously from eight ER-positive and four ER-negative patients. Tissue biopsies were sequenced by NGS, and ptDNA ESR1 mutations were analyzed by ddPCR. Results: In the retrospective cohort, all corresponding mutations were detected in ptDNA, with two patients harboring additional ESR1 mutations not present in their metastatic tissues. In the prospective cohort, three ER-positive patients did not have adequate tissue for NGS, and no ESR1 mutations were identified in tissue biopsies from the other nine patients. In contrast, ddPCR detected seven ptDNA ESR1 mutations in 6 of 12 patients (50%). Conclusions: We show that ESR1 mutations can occur at a high frequency and suggest that blood can be used to identify additional mutations not found by sequencing of a single metastatic lesion. Clin Cancer Res; 22(4); 993–9. ©2015 AACR.

1 April 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
TKTae Hyun Kim
Tae Hyun Kim
YWYang Wang
Yang Wang
COC. Ryan Oliver
C. Ryan Oliver
DTDouglas H. Thamm
Douglas H. Thamm
LCLaura Cooling
Laura Cooling
DHDaniel F. Hayes
Daniel F. Hayes
Circulating tumor cells (CTCs) have become an established biomarker for prognosis in patients with various carcinomas. However, current ex vivo CTC isolation technologies rely on small blood volumes from a single venipuncture limiting the number of captured CTCs. This produces statistical variability and inaccurate reflection of tumor cell heterogeneity. Here, we describe an in vivo indwelling intravascular aphaeretic CTC isolation system to continuously collect CTCs directly from a peripheral vein. The system returns the remaining blood products after CTC enrichment, permitting interrogation of larger blood volumes than classic phlebotomy specimens over a prolonged period of time. The system is validated in canine models showing capability to screen 1–2% of the entire blood over 2 h. Our result shows substantial increase in CTC capture, compared with serial blood draws. This technology could potentially be used to analyze large number of CTCs to facilitate translation of analytical information into future clinical decisions.

31 May 2015 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
CPCostanza Paoletti
Costanza Paoletti
MMMaria C. Muñiz
Maria C. Muñiz
DTDafydd G. Thomas
Dafydd G. Thomas
KGKent A. Griffith
Kent A. Griffith
KKKelley M. Kidwell
Kelley M. Kidwell
DHDaniel F. Hayes
Daniel F. Hayes
Background: Endocrine therapy (ET) fails to induce a response in one half of patients with hormone receptor (HR)–positive metastatic breast cancer (MBC), and almost all will eventually become refractory to ET. Circulating tumor cells (CTC) are associated with worse prognosis in patients with MBC, but enumeration alone is insufficient to predict the absolute odds of benefit from any therapy, including ET. We developed a multiparameter CTC-Endocrine Therapy Index (CTC-ETI), which we hypothesize may predict resistance to ET in patients with HR-positive MBC. Methods: The CTC-ETI combines enumeration and CTC expression of four markers: estrogen receptor (ER), B-cell lymphoma 2 (BCL-2), Human Epidermal Growth Factor Receptor 2 (HER2), and Ki67. The CellSearch System and reagents were used to capture CTC and measure protein expression by immunofluorescent staining on CTC. Results: The feasibility of determining CTC-ETI was initially established in vitro and then in a prospective single-institution pilot study in patients with MBC. CTC-ETI was successfully determined in 44 of 50 (88%) patients. Eighteen (41%), 9 (20%), and 17 (39%) patients had low, intermediate, and high CTC-ETI scores, respectively. Interobserver concordance of CTC-ETI determination was from 94% to 95% (Kappa statistic, 0.90–0.91). Inter- and cell-to-cell intrapatient heterogeneity of expression of each of the CTC markers was observed. CTC biomarker expression was discordant from both primary and metastatic tissues. Conclusions: CTC expression of ER, BCL-2, HER2, and Ki67 can be reproducibly measured with high analytical validity using the CellSearch System. The clinical implications of CTC-ETI, and of the heterogeneity of CTC biomarker expression, are being evaluated in an ongoing prospective trial. Clin Cancer Res; 21(11); 2487–98. ©2014 AACR. See related commentary by Mathew et al., p. 2421